Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

2.

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.

Daskalopoulou SS, Mikhailidis DP.

Curr Med Res Opin. 2006 Mar;22(3):511-28. Review.

PMID:
16574035
3.

Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis.

Mikhailidis DP, Lawson RW, McCormick AL, Sibbring GC, Tershakovec AM, Davies GM, Tunceli K.

Curr Med Res Opin. 2011 Jun;27(6):1191-210. doi: 10.1185/03007995.2011.571239. Epub 2011 Apr 7. Review.

PMID:
21473671
4.

[A new approach to the treatment of dyslipidemia].

Kevelaitiene S, Slapikas R.

Medicina (Kaunas). 2008;44(5):407-13. Review. Lithuanian.

5.

Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor.

Jeu L, Cheng JW.

Clin Ther. 2003 Sep;25(9):2352-87. Review.

PMID:
14604738
6.

Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.

Robinson JG, Davidson MH.

Expert Rev Cardiovasc Ther. 2006 Jul;4(4):461-76. Review. Erratum in: Expert Rev Cardiovasc Ther. 2006 Sep;4(5):772.

PMID:
16918265
7.

[Ezetimibe: from pharmacology to clinical trials].

Tellier P.

Ann Endocrinol (Paris). 2003 Dec;64(6):442-7. Review. French.

PMID:
15067249
8.
9.

Dual inhibition, newer paradigms for cholesterol lowering.

Katragadda S, Rai F, Arora R.

Am J Ther. 2010 Jul-Aug;17(4):e88-99. doi: 10.1097/MJT.0b013e31815adf85. Review.

PMID:
20634651
10.

Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?

Fitchett DH, Leiter LA, Tardif JC, Goodman S, Langer A.

Can J Cardiol. 2005 Jan;21(1):85-90. Review.

PMID:
15685308
11.

Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?

Husain NE, Hassan AT, Elmadhoun WM, Ahmed MH.

Expert Opin Drug Saf. 2015;14(9):1445-55. doi: 10.1517/14740338.2015.1063613. Epub 2015 Jul 3. Review.

PMID:
26134926
12.

[The role of intestinal absorption blockade in hypercholesterolemia treatment].

Diz-Lois F.

Rev Clin Esp. 2004 Oct;204(10):554-60. Review. Spanish. Erratum in: Rev Clin Esp. 2004 Dec;204(12):663.

PMID:
15456613
13.

Optimizing lipid lowering in patients at risk.

Clark LT.

Clin Cardiol. 2004 Jun;27(6 Suppl 3):III22-6. Review.

14.

Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management.

Leitersdorf E.

Int J Clin Pract. 2002 Mar;56(2):116-9. Review.

PMID:
11926698
15.

Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years.

Lioudaki E, Ganotakis ES, Mikhailidis DP.

Curr Vasc Pharmacol. 2011 Jan;9(1):62-86. Review.

PMID:
21044019
16.

[Statins: for the time being, do not as a rule prescribe the maximum dose].

Smulders YM.

Ned Tijdschr Geneeskd. 2005 Aug 20;149(34):1876-8. Review. Dutch. Erratum in: Ned Tijdschr Geneeskd. 2005 Nov 12;149(46):2592.

PMID:
16136739
18.

Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.

Gazi IF, Mikhailidis DP.

Expert Opin Ther Targets. 2006 Dec;10(6):851-66. Review.

PMID:
17105372
19.

[Which cholesterol-lowering drugs should be used in the primary prevention of cardiovascular disease?].

Fretheim A, Bjørndal A, Oxman AD, Dyrdal A, Golding M, Ose L, Reikvam A, Teisberg P.

Tidsskr Nor Laegeforen. 2002 Sep 30;122(23):2287-8. Review. Norwegian.

PMID:
12448270
20.

Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia.

Burnett JR, Huff MW.

Expert Opin Investig Drugs. 2006 Nov;15(11):1337-51. Review.

PMID:
17040195

Supplemental Content

Support Center